CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Vtama (tapinarof) cream

Clinical coverage policy for Vtama (tapinarof) cream for plaque psoriasis (adults) and atopic dermatitis (ages 2+) including initial and continuation authorization criteria, quantity limits, and concomitant use restrictions. Also states that other indications are considered experimental/investigational.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVtama (tapinarof) cream

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2025

Next Review Date

Key ActionDocument BSA and prior therapy trials and ensure authorization requests meet the listed clinical criteria including specialist involvement, prior therapy failures, BSA documentation, and quantity limit justification.

POLICY UPDATE CHANGES

No material clinical/coverage changes.

2Covered Indications

60Quantity Limit (g/30d)

2Min age for AD

18Min age for Psoriasis

Coverage Summary

Coverage stance: Covered with criteria for the FDA‑approved indications listed below when all approval criteria are met and the member has no exclusions.

Key thresholds

Body Surface Area (Plaque Psoriasis)3-20% BSA documented

Plaque psoriasis: topical corticosteroid trial2-4 consecutive weeks of high or super-high potency within last 12 months

Atopic dermatitis: minimum age2 years and older

Plaque psoriasis: minimum age18 years and older

Atopic dermatitis: topical agent trial durationsTacrolimus 6 consecutive weeks; Pimecrolimus 6 consecutive weeks; Eucrisa 4 consecutive weeks

Zoryve trial windowWithin the last 12 months (psoriasis: roflumilast 0.3%; AD ≥6 years: roflumilast 0.15%)

Quantity limit60 grams per 30 days

Plaque Psoriasis — Initial Authorization (12 months)

Plaque Psoriasis (Initial authorization — 12 months)

Initial authorization may be granted when ALL of the following are met:

ALL of the following

Member is 18 years of age or older; diagnosed with plaque psoriasis
Vtama is prescribed by, or in consultation with, a specialist in dermatology or rheumatology
BSA 3-20%: Documentation of affected area(s) and that the affected body surface area (BSA) is between 3-20%. Documentation of BSA affected is provided.BSA 3-20%
Topical corticosteroid trial: Documentation that the member experienced an inadequate treatment response to at least a 2-4 consecutive week trial within the last 12 months of a high or super-high potency topical corticosteroid (e.g., betamethasone, clobetasol). Contraindications, adverse effects and/or intolerance must be documented.2-4 consecutive weeks within last 12 months
Prior combination therapies (2 of the following)
- Topical vitamin D analogs (e.g., calcipotriene 0.005% ointment, cream, solution)
- Phototherapy
- Topical retinoid (e.g., tazarotene cream 0.1%)
- Oral systemic non-biologic drugs (e.g., methotrexate, cyclosporine, acitretin)
Biologic switch exemption: If the member is switching from a biologic for psoriasis treatment, the member is not required to trial Zoryve before Vtama
Zoryve trial: Documentation that the member experienced an inadequate treatment response or intolerance from Zoryve (roflumilast) cream 0.3% within the last 12 months. Contraindications, adverse effects and/or intolerance must be documented.Within the last 12 months
Concomitant use prohibition: Vtama will not be used concomitantly with Zoryve (roflumilast) cream, any therapeutic biologic drug (e.g., adalimumab, infliximab), or any targeted synthetic drug (e.g., apremilast).
Concomitant use prohibition

Documentation Required

Document BSA and prior therapy trials

Provider must document affected area(s) and body surface area (BSA). For plaque psoriasis initial authorization, BSA must be documented as between 3–20%. Also document inadequate response, intolerance, or contraindications to required prior therapies with specified trial durations within the last 12 months where applicable.

Atopic Dermatitis — Initial Authorization (12 months)

Atopic Dermatitis (Initial authorization — 12 months)

Initial authorization may be granted when ALL of the following are met:

ALL of the following

Member is 2 years of age or older
Member has a diagnosis of atopic dermatitis (AD). Documentation of BSA affected is provided.
Vtama is prescribed by, or in consultation with, a specialist in dermatology or immunology/allergy
Topical corticosteroid trial: Documentation that member experienced an inadequate treatment response or intolerance to at least one medium to super-high potency topical corticosteroid for at least 2 consecutive weeks. Contraindications, adverse effects and/or intolerance must be documented.At least 2 consecutive weeks
Calcineurin/Eucrisa trial: Documentation that member experienced an inadequate treatment response or intolerance to one of the following: topical tacrolimus ointment for 6 consecutive weeks, pimecrolimus cream for 6 consecutive weeks, and/or Eucrisa (crisaborole) ointment for 4 consecutive weeks. Contraindications, adverse effects and/or intolerance must be documented.Tacrolimus 6 weeks; Pimecrolimus 6 weeks; Eucrisa 4 weeks
Zoryve trial for >=6 years: For members 6 years of age or older with mild to moderate disease, documentation that the member experienced an inadequate treatment response or intolerance from Zoryve (roflumilast) cream 0.15% within the last 12 months. Contraindications, adverse effects and/or intolerance must be documented.Within the last 12 months; applies to >=6 years
Concomitant use prohibition: Vtama will not be used concomitantly with Eucrisa (crisaborole) ointment, Opzelura (ruxolitinib) cream, Zoryve (roflumilast) cream, any therapeutic biologic, or any targeted synthetic drug.
Concomitant use prohibition
Biologic switch exemption: If the member is switching from a biologic for AD treatment, the member is not required to trial Zoryve before Vtama

Documentation Required

Document BSA and prior therapy trials (AD)

For AD initial authorization, document the affected area(s) and BSA, plus prior therapy trials and any documented intolerance/contraindication. Include trial durations for topical corticosteroids and other required prior agents as listed in the criteria.

Continuation of Therapy (12 months)

Authorization of 12 months may be granted when ALL of the following are met:

ALL of the following

Improvement evidence (any)
- Improvement in signs and symptoms from baseline (e.g., itching, redness, flaking, scaling, burning, cracking, pain, clear or almost clear skin)
- Reduction in body surface area affected from baseline (BSA)
Concomitant use prohibition for continuation: Vtama will not be used concomitantly with Zoryve (roflumilast) cream, Eucrisa (crisaborole) ointment, Opzelura (ruxolitinib) cream, any therapeutic biologic drug (e.g., adalimumab, infliximab), or any targeted synthetic drug (e.g., apremilast, upadacitinib).
Concomitant use prohibition for continuation

Denial Risk

Concomitant therapy exclusions — denial risk

Claims will be noncompliant/denied if Vtama is used concomitantly with the listed topical products, any therapeutic biologic drug, or any targeted synthetic drug.

Prohibited topical products: Zoryve (roflumilast), Eucrisa (crisaborole), Opzelura (ruxolitinib)
Any therapeutic biologic drug (e.g., adalimumab, infliximab)
Any targeted synthetic drug (e.g., apremilast, upadacitinib)

Provider Actions / Billing

Prior Authorization

Prior authorization required

Prior authorization required — documentation of listed clinical criteria is needed prior to approval.

Documentation Required

Required documentation

Document the following for initial and continuation requests:

Age (plaque psoriasis: ≥18 years; AD: ≥2 years)
Diagnosis (plaque psoriasis or atopic dermatitis)
Prescribing specialist or consult (dermatology, rheumatology, or immunology/allergy)
Body surface area (BSA) affected (plaque psoriasis: 3–20%)
Names and durations of prior therapies tried within specified windows
Documented intolerance, adverse effects, or contraindications to prior therapies

Billing Rule

Quantity limit enforcement

Vtama cream 1% is limited to 60 grams per 30 days; claims exceeding this quantity require justification and may be denied.

Denial Risk

Concomitant therapy exclusions — denial risk

Vtama must not be used concomitantly with the specified topical agents, any therapeutic biologic, or any targeted synthetic agent; claims or requests that show concomitant use with these agents are noncompliant and may be denied.

Eucrisa (crisaborole) ointment
Opzelura (ruxolitinib) cream
Zoryve (roflumilast) cream
Any therapeutic biologic (e.g., adalimumab, infliximab)
Any targeted synthetic drug (e.g., apremilast, upadacitinib)

Background

Background: Vtama (tapinarof) cream is a topical therapy indicated for plaque psoriasis in adults and atopic dermatitis in patients aged 2 years and older. The policy is based on the FDA‑approved product information (December 2024) and establishes prior‑therapy requirements, documentation (including body surface area), quantity limits, and exclusions for concomitant use with specified topical agents, biologics, and targeted synthetic drugs.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyVtama (tapinarof) cream

Policy CodePolicy N/A

Change TypeNo material change

Effective DateFeb 1, 2025

Next Review Date

On This Page

OpenPayer

Vtama (tapinarof) cream

Coverage Summary

Plaque Psoriasis — Initial Authorization (12 months)

Atopic Dermatitis — Initial Authorization (12 months)

Continuation of Therapy (12 months)

Unproven / Not Medically Necessary

Applicable Codes

Provider Actions / Billing

Clinical Evidence & References

Background

Revision History